With ‘Cure’ Comment, Trump Exaggerates Known Benefits of Another Covid-19 Therapy

Experts think monoclonal antibodies, like the cocktail taken by Mr. Trump, could fare better than hydroxychloroquine and convalescent plasma.

The treatment is “super promising, and all of us are excited from a theoretical perspective,” Dr. Ranney said. “But it’s just too early,” she added, to tell if theory will translate into practice.

Monoclonal antibodies are synthetic, mass-produced mimics of the molecules the human body produces in response to an infection. Some antibodies are powerful enough to block the coronavirus from infiltrating cells. Administered to people battling the coronavirus, the monoclonal antibodies could help naturally produced immune molecules fend off the virus.

Just days before Mr. Trump tested positive for the coronavirus and was admitted to the hospital, Regeneron announced a batch of preliminary results, collected from ongoing trials, via news release. They suggested Regeneron’s monoclonal antibody cocktail could tamp down the amount of virus found in the nasal cavity, and

Read More

Wells Fargo CEO sorry for ‘insensitive comment’ on diversity

Wells Fargo & Co Chief Executive Officer Charles Scharf has apologized for making insensitive remarks around race and diversity, seeking to quell a row over his references to a shortage of talent among minority groups.

Reuters reported on Tuesday that Scharf had exasperated some Black employees in a Zoom meeting this summer when he reiterated that the bank had trouble reaching diversity goals because there were not enough qualified minority candidates.

He also made the assertion in a company-wide memo on June 18 that announced diversity initiatives as nationwide protests broke out following the death of George Floyd, an unarmed African-American man, in police custody.

“There are many talented diverse individuals working at Wells Fargo and throughout the financial services industry and I never meant to imply otherwise,” Scharf said in a statement on Wednesday.

“Across the industry, we have not done enough to improve diversity, especially at senior leadership

Read More